Related Experiment Videos
Abstract:
At least 80 per cent of prostatic tumors exhibit some degree of hormone responsiveness. The preferred method of hormonal alteration has yet to be determined because new agents are currently undergoing clinical trials. The compounds tested have included cyproterone acetate, a progestational agent; flutamide, an antiandrogen that blocks the DHT-receptor complex in the tumor cell; and aminoglutethimide, which inhibits adrenal steroid production and, therefore, might further lower the level of circulating androgen following bilateral orchiectomy. The introduction of potent, synthetic analogues of gonadotropin-releasing hormone (GnRH) has provided another method of reducing the level of circulating androgen. A recent report on the efficacy of one of these analogues--leuprolide--in men with newly diagnosed metastatic prostatic cancer has revealed an initial response rate of 76 per cent (4% complete remissions, 32% partial remissions, and 40% stable) using National Prostatic Cancer Project criteria.
Insights
Hormone therapy is crucial for treating prostate cancer, with new agents like GnRH analogues showing promise. Leuprolide, a gonadotropin-releasing hormone analogue, achieved a 76% response rate in metastatic prostate cancer patients.
Area of Science:
- Oncology
- Endocrinology
Background:
- Prostate tumors often exhibit hormone responsiveness, making hormonal therapy a key treatment modality.
- The optimal hormonal alteration strategy remains under investigation due to ongoing clinical trials of novel agents.
Purpose of the Study:
- To evaluate the efficacy of novel hormonal agents in managing prostate cancer.
- To assess the response rate of leuprolide, a gonadotropin-releasing hormone (GnRH) analogue, in patients with newly diagnosed metastatic prostate cancer.
Main Methods:
- Review of clinical trials involving hormonal agents such as cyproterone acetate, flutamide, aminoglutethimide, and GnRH analogues.
- Analysis of a recent report on the efficacy of leuprolide in men with metastatic prostate cancer.
Main Results:
- Leuprolide, a synthetic GnRH analogue, demonstrated an initial response rate of 76% in patients with newly diagnosed metastatic prostate cancer.
- The response breakdown for leuprolide included 4% complete remissions, 32% partial remissions, and 40% stable disease, according to National Prostatic Cancer Project criteria.
Conclusions:
- Synthetic GnRH analogues, such as leuprolide, represent a viable method for reducing circulating androgen levels in prostate cancer treatment.
- Leuprolide shows significant efficacy in achieving disease control for patients with metastatic prostate cancer, warranting further investigation.